



(51) International Patent Classification:

C07K 16/22 (2006.01) *C07K 16/28* (2006.01)
A61P 35/04 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:

PCT/IB2019/056932

(22) International Filing Date:

15 August 2019 (15.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/765,289	20 August 2018 (20.08.2018)	US
62/750,393	25 October 2018 (25.10.2018)	US
62/750,479	25 October 2018 (25.10.2018)	US
62/881,064	31 July 2019 (31.07.2019)	US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).


(72) Inventors: **BEAUMONT, Kevin Charles**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **BREEN, Danna M.**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **CHABOT, Jeffrey Raymond**; c/o Pfizer Inc., 610 Main Street, Cam-

bridge, Massachusetts 02139 (US). **HE, Tao**; 51 Canterbury Hill Road, Acton, Massachusetts 01720 (US). **SHCHORS, Ksenya**; 1306 Ashwood Ct., San Mateo, California 94402 (US). **APGAR, James R.**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **LAMBERT, Matthew Allister**; c/o Pfizer Ireland Pharmaceuticals, Grange Castle Business Park, Clondalkin, Dublin, 22 (IE).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE

FIG. 5

(57) Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

07 May 2020 (07.05.2020)